Detalles de la búsqueda
1.
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Lancet Oncol
; 17(5): 622-31, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27049457
2.
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
Blood
; 119(18): 4123-8, 2012 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-22371887
3.
Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma.
Leuk Lymphoma
; 61(12): 2939-2946, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32666852
4.
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Leuk Lymphoma
; 59(4): 863-870, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28792260
5.
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Blood Cancer J
; 8(6): 60, 2018 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29895903
Resultados
1 -
5
de 5
1
Próxima >
>>